Skip to main content
. Author manuscript; available in PMC: 2020 Feb 1.
Published in final edited form as: Neuropharmacology. 2018 Sep 17;145(Pt B):268–282. doi: 10.1016/j.neuropharm.2018.09.024

Figure 8.

Figure 8.

Confocal micrographs double-labeled with BrdU (green) and DCX (red) at 7 days post CCI in the mouse with P7C3–A20 administration. Double-labeled cell bodies and processes are visible in the ipsilateral DG (top panels). Quantification of cells coexpressing BrdU/DCX are shown (bottom). P7C3–A20 administration coupled with moderate CCI significantly increased the estimated population of BrdU/DCX cells relative to sham controls at this early posttraumatic time point. n = 4–5/group, one-way ANOVA, *p = 0.012, DF, 2. Tukey post hoc **p = 0.0095, DF, 10.

HHS Vulnerability Disclosure